The continued poor rates of blood pressure (BP) control to the recommended target BP of Ͻ140/90 mm Hg in patients with hypertension indicate a persistent need for improved antihypertensive therapy. Angiotensin II receptor blockers (ARBs) constitute the newest approved class of antihypertensive agents. As with angiotensin converting enzyme inhibitors, ARBs block the renin-angiotensinaldosterone system, but do so through a more specific mechanism.
T
he elevated morbidity and mortality risks associated with hypertension and the clinical benefits of blood pressure (BP) control have been clearly established. [1] [2] [3] [4] [5] Despite hypertension guidelines clearly recommending a goal BP of Ͻ140/90 mm Hg, 1, 6 the rate of BP control remains poor worldwide. Of the approximately 50 million persons in the United States with hypertension, only about 27% control their BP to Ͻ140/90 mm Hg, according to data from the National Health and Nutrition Examination Survey, Phase III (NHANES III). 7, 8 Furthermore, the patients with controlled BP represent only about one half of those being treated for hypertension. 7, 8 In other nations where the goal BP level of Ͻ140/90 mm Hg is generally recommended and accepted, control rates are estimated at 6% (England), 22% (Canada), and 24% (France). 9 -11 In countries where a less aggressive target BP of Ͻ160/95 mm Hg is more commonly accepted, control rates still range from about 9% (India) to 22.5% (Germany). 12 These epidemiologic data indicate that enhanced therapeutic strategies for the management of hypertension are necessary to improve BP control. Because the success of antihypertensive therapy often depends on tolerability and patient adherence, antihypertensive medications must have excellent tolerability as well as high BP-lowering efficacy.
The newest class of antihypertensive drugs, angiotensin II receptor blockers (ARBs), is an excellent addition to the armamentarium of agents that are available for management of hypertension. In clinical trials, ARBs have been shown to have similar BP-lowering efficacy and superior tolerability when compared with other leading classes of antihypertensive medications. 13, 14 Studies have also demonstrated that ARBs provide significant protection against diabetic nephropathy and cardiovascular morbidity and mortality that is independent of their BP-lowering effect. [15] [16] [17] [18] Olmesartan medoxomil is the newest of the ARBs. This recently approved agent has been shown in clinical trials to have a safety and tolerability profile similar to that of placebo, as well as antihypertensive efficacy at least as good as that of drugs in other antihypertensive classes. 19, 20 Olmesartan medoxomil has also been shown to have antihypertensive efficacy superior to that of other ARBs. 19, 21 As one of the most effective agents in a promising class of drugs, olmesartan medoxomil may be useful for helping clinicians to meet increasingly aggressive standards for treatment of hypertension.
Mechanism of Action
As an ARB, olmesartan medoxomil lowers BP by blocking the action of angiotensin II (Ang II), the main peptide effector of the renin-angiotensin-aldosterone system (RAAS). 22 High plasma renin activity is well known as a major risk factor for hypertension and for cardiovascular and renal morbidity and mortality. 13 The RAAS is an enzymatic cascade involving the conversion of angiotensinogen to angiotensin I and angiotensin I to Ang II, a potent vasoconstrictor. 13, 23 Angiotensin II can bind to several receptors, most notably the angiotensin II type 1 (AT 1 ) and angiotensin II type 2 (AT 2 ) receptors. The AT 1 receptor is known to mediate virtually all of the deleterious actions of Ang II; the role of the AT 2 receptor, however, is poorly understood. 13, 23, 24 The effects of inhibiting the RAAS were first demonstrated with the use of angiotensin converting enzyme (ACE) inhibitors, which block the enzyme principally responsible for converting angiotensin I to Ang II. 13 Angiotensin converting enzyme inhibitors have been found to lower BP significantly while providing greater target organ protection than that of agents in other leading antihypertensive drug classes. 1, [25] [26] [27] [28] [29] [30] However, Ang II can be generated by other pathways. 23 Moreover, ACE inhibitors inhibit the breakdown of plasma bradykinin, thereby promoting the accumulation of bradykinin, which may be associated with two common adverse effects associated with ACE inhibitor therapy: a dry cough and increased risk of angioedema.
Olmesartan medoxomil selectively blocks the binding of Ang II to the AT 1 receptor, thereby reducing vascular resistance and lowering BP (Fig. 1) . 24, 31 Angiotensin II may continue to bind with the AT 2 receptor, which may further counteract the harmful effects of AT 1 receptor stimulation. 24, 32 This mechanism of action provides more specific and potentially more complete RAAS blockade than does ACE inhibitor therapy. 33 The inhibition of Ang II-induced contractions has been studied in aortas isolated from male Hartley guinea pigs; this is an excellent model for in vitro study of the Ang II antagonism characteristics of a particular agent. In one study, olmesartan medoxomil markedly reduced maximal Ang II-induced contractions in isolated guinea pig aortas in a dose-dependent manner, with little shift to the right of the concentration-response curve (Fig. 2) . 33 These results indicate noncompetitive inhibition of Ang II by olmesartan medoxomil in vascular tissue.
Pharmacokinetics
Olmesartan medoxomil is an ARB with linear pharmacokinetics over a wide dose range. 33, 34 Olmesartan medoxomil is a prodrug; after oral administration, it rapidly undergoes de-esterification within the intestinal wall to release its active metabolite, olmesartan. 34 Only the active metabolite is detected in plasma. 35 After this hydrolytic process, olmesartan is not metabolized further. It is the only compound detected in urine and feces 36 : about 35% to 50% of the absorbed dose is excreted in urine; the remainder undergoes elimination through the biliary tract and is excreted through feces. 34 The bioavailability of olmesartan is approximately 25%; relatively low variability is observed for this parameter. More than 99% of a dose binds with serum albumin, Ͼ96% with ␣ 1 -acid glycoproteins, and Ͻ14% with human globulin. 34, 36 Administration of olmesartan medoxomil in single daily doses of up to 80 mg for 10 days did not result in drug accumulation. 34 T max is achieved in approximately 2 h. 34 Compared with many of the other ARBs, olmesartan has a long half-life (approximately 13 h), and it can be taken with or without meals. It is not metabolized by the hepatic cytochrome P450 enzyme system; thus, the risk of drug interactions is reduced. 34 No clinically significant pharmacokinetic interactions were observed in studies of olmesartan medoxomil coadministered with digoxin or warfarin. 33 Neutralization of gastric pH with antacids also did not significantly reduce the bioavailability of olmesartan medoxomil.
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Efficacy and Safety Versus Placebo
Efficacy and safety data for olmesartan medoxomil were pooled from seven randomized, double-blind, placebocontrolled, parallel-group Phase II and Phase III studies involving 2693 subjects, 2145 of whom were included in an efficacy analysis. 20 All were multicenter studies conducted in Europe and the US.
Enrolled subjects were men and women Ն18 years of age with a diagnosis of essential hypertension and a seated diastolic BP (SeDBP) of Ն100 mm Hg to Յ115 mm Hg. The primary efficacy variable for all studies was the mean change from baseline in mean trough SeDBP at the study end point, which varied from 6 to 12 weeks. Secondary variables included the change from baseline in trough seated systolic BP (SeSBP), heart rate, trough standing diastolic BP (DBP) and systolic BP (SBP), mean 24-h DBP and SBP, and responder rate (SeDBP Ͻ90 mm Hg or at least a 10-mm Hg reduction from baseline in SeDBP). Of the 2693 subjects enrolled, 2145 received olmesartan medoxomil and 548 received placebo.
The mean change from baseline in both SeDBP and SeSBP was significantly greater than for placebo in all olmesartan medoxomil-treated groups (P Ͻ .001). 20 The degree of BP reduction was dose dependent (Fig. 3) . The reduction in mean SeDBP from baseline to the primary study time point was 6.2 mm Hg for placebo, 9.8 mm Hg for olmesartan medoxomil 5 mg, 12.2 mm Hg for olmesartan medoxomil 20 mg/day, and 13.1 mm Hg for olmesartan medoxomil 40 mg/day. The mean reductions in mean SeSBP from baseline to the primary study time point were 5.6 mm Hg for placebo, 12.4 mm Hg for olmesartan medoxomil 5 mg/day, 15.1 mm Hg for olmesartan medoxomil 20 mg/day, and 17.6 mm Hg for olmesartan medoxomil 40 mg/day.
The antihypertensive response to olmesartan medoxomil was evident within the first week of treatment, and the majority of the antihypertensive responses were produced within 2 weeks of initiation of treatment. These results were generally consistent across sex and age categories.
In the safety analysis, 2540 subjects received olmesartan medoxomil and 555 were given placebo. 20 The adverse event (AE) rates were similar for the two groups: 42.2% of subjects in the olmesartan medoxomil treatment group and 42.7% of those in the placebo group experienced at least one treatment-emergent AE. Most of the events were mild and were judged by investigators to be unrelated to treatment. There was no relationship between the AE rate and the olmesartan medoxomil dose.
In one of the placebo-controlled trials, the effect of once-daily versus twice-daily dosing of olmesartan medoxomil was assessed over 24 h via ambulatory blood pressure monitoring (ABPM). Based on ambulatory BP measurements, olmesartan medoxomil 20 mg (10 mg twice daily or 20 mg once daily) produced a trough:peak ratio of 63%. Furthermore, it was effective in reducing both DBP (Fig. 4) and SBP over the entire 24-h period, whether given as 10 mg twice daily or as 20 mg once daily. Both olmesartan medoxomil dosing regimens reduced ambulatory DBP and SBP significantly compared with placebo (P Ͻ .001), and twice-daily dosing provided no clinical advantage over once-daily dosing. These results support once-daily dosing with olmesartan medoxomil.
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Efficacy Versus Other Drug Classes
In clinical trials, olmesartan medoxomil provided similar BP-lowering efficacy compared with other leading antihypertensive agents. 
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Olmesartan Medoxomil Versus Atenolol
In a randomized, double-blind, 12-week comparison study, subjects (n ϭ 326) with mild-to-moderate essential hypertension (SeDBP 95 to 114 mm Hg) were given olmesartan medoxomil 10 mg/day (n ϭ 165) or the ␤-blocker atenolol 50 mg/day (n ϭ 161). 38 Doubling of the dose of either drug was allowed if the DBP was Ն90 mm Hg, if DBP decreased by Ͻ10 mm Hg, or both. The primary end point was the change in mean trough SeDBP from baseline to Week 12.
The reduction in SeDBP was similar for the olmesartan medoxomil group (14.0 mm Hg) and the atenolol group (14.3 mm Hg). The reduction in SeSBP was significantly greater (P ϭ .05) in subjects given olmesartan medoxomil (20.7 mm Hg) than in subjects given atenolol (17.2 mm Hg). About one third of the subjects in each treatment group required uptitration to the higher dose to reach BP goals.
Olmesartan Medoxomil Versus Amlodipine Besylate
In this double-blind, multicenter study, subjects (n ϭ 440) with mild-to-moderate hypertension (SeDBP, 100-115 mm Hg; daytime ambulatory DBP [ADBP] 90 -119 mm Hg) were randomized to 8 weeks of therapy with placebo (n ϭ 66), the calcium channel blocker amlodipine besylate 5 mg (n ϭ 186), or olmesartan medoxomil 20 mg (n ϭ 188). 39 The primary end point was the change from baseline in mean 24-h ADBP.
There was no statistically significant difference in the reduction in 24-h ambulatory BP achieved using olmesartan medoxomil (13.0/8.2 mm Hg) v amlodipine besylate (12.9/ 7.4 mm Hg). 39 Reductions in cuff SeSBP/SeDBP were also similar for olmesartan medoxomil (10.9/10.6 mm Hg) and amlodipine besylate (10.9/9.7 mm Hg). Both agents produced a significantly greater reduction in BP compared with placebo (P Ͻ .001). Both agents were well tolerated overall, although subjects in the amlodipine besylate group had a significantly higher incidence of nausea (2.7%; P ϭ .039) than did subjects in the olmesartan medoxomil group (0.0%), and there was a tendency for the incidence of edema to be higher in the amlodipine besylate group (9.1%) than in the olmesartan medoxomil group (4.3%).
Olmesartan Medoxomil Versus Felodipine
In a head-to-head 12-week trial, subjects (n ϭ 378) with moderate-to-severe hypertension (SeDBP Ն100 mm Hg to Յ120 mm Hg) were randomized to receive olmesartan medoxomil 20 mg/day (n ϭ 186) or felodipine 5 mg/day (n ϭ 192); the dose was doubled if the reduction in BP was Ͻ10 mm Hg by Week 8 (unpublished data, Sankyo Pharma, Inc., 2002). Blood pressure reductions at Week 12 were similar for both treatment groups (19.9/17.5 mm Hg for olmesartan medoxomil v 19.1/17.0 mm Hg for felodipine) (unpublished data, Sankyo Pharma, Inc., 2002). Of the subjects treated with olmesartan medoxomil, 31.7% were titrated to the higher dose at Week 4, compared with 39.6% of subjects in the felodipine group. Both trial drugs were well tolerated. Peripheral edema occurred in five patients in the felodipine group and in none of the subjects given olmesartan medoxomil.
Efficacy Versus Other ARBs
Olmesartan medoxomil has been shown to have greater antihypertensive efficacy compared with that of the leading ARBs.
Olmesartan Medoxomil Versus Losartan Potassium
In a randomized, double-blind study, olmesartan medoxomil was compared with the first available ARB, losartan potassium. 19 Subjects (n ϭ 316) with mild-to-moderate hypertension (SeDBP between Ն95 mm Hg and Յ114 mm Hg) were randomized to treatment with olmesartan medoxomil 10 mg/day or losartan potassium 50 mg/day for 24 weeks. After 4 weeks of treatment, the dose was doubled in subjects with an SeDBP Ն90 mm Hg, a decrease in BP from baseline of Ͻ10 mm Hg, or both. At Weeks 12, 16, and 20, hydrochlorothiazide (HCTZ) was added to the regimen and subsequently uptitrated if SeDBP was still not controlled. The primary end point was the change from baseline in trough SeDBP at Week 12 (when all subjects were still receiving monotherapy).
At Week 12, subjects receiving olmesartan medoxomil had a significantly greater (P Ͻ .05) reduction in SeDBP (10.6 mm Hg) than did those given losartan potassium (8.5 mm Hg). 19 The reduction in SeDBP in patients treated with olmesartan medoxomil (9.1 mm Hg) was also significantly greater (P Ͻ .05) at Week 4 than in patients administered losartan potassium (6.4 mm Hg). Fewer subjects in the olmesartan medoxomil group than in the losartan potassium group required titration to the higher dose level (55% v 77%) or the addition of HCTZ (35% v 48%), and the differences in SeDBP observed at Week 24 (12.9 v 11.6 mm Hg with olmesartan medoxomil and losartan potassium, respectively) did not reach statistical significance.
Olmesartan Medoxomil Versus Three Other ARBs
The antihypertensive efficacy of olmesartan medoxomil was compared with that of losartan potassium, valsartan, and irbesartan in a multicenter, randomized, double-blind study. 21 Subjects (n ϭ 588) with mild-to-moderate essential hypertension (SeDBP of Ն100 mm Hg to Յ115 mm Hg and a mean daytime ADBP of Ն90 to Յ120 mm Hg) were randomized to the recommended starting dosages of olmesartan medoxomil (20 mg/day), losartan potassium (50 mg/day), valsartan (80 mg/day), or irbesartan (150 mg/day) once daily. The primary end point was the change from baseline in cuff SeDBP at Week 8. The reduction in SeDBP achieved by olmesartan medoxomil (11.5 mm Hg) was significantly greater than that demonstrated by each of the other three ARBs (P Ͻ .001 v losartan potassium; P Ͻ .001 v valsartan; P ϭ .04 v irbesartan) (Fig. 5) . 21 The reduction in 24-h mean ambulatory BP in subjects given olmesartan medoxomil (12.5/8.5 mm Hg) was significantly greater than that observed in the losartan potassium (9.0/6.2 mm Hg) and valsartan (8.1/5.6 mm Hg) groups (P Ͻ .05 for each comparison) and showed a trend toward a greater reduction than was observed in the irbesartan group (11.3/7.4 mm Hg). All ARBs were well tolerated.
Olmesartan Medoxomil in Combination Therapy
Major studies have shown that achieving currently recommended BP goals requires the administration of multiple antihypertensive agents in combination. 4,40 -42 Olmesartan medoxomil has been shown to be safe and effective when used in combination with other antihypertensive agents.
Olmesartan Medoxomil/HCTZ
In a randomized, controlled, factorial-design study, subjects (n ϭ 502) with moderate-to-severe essential hypertension (mean SeDBP of Ն100 mm Hg to Յ115 mm Hg) were randomized to one of 12 groups for treatment with olmesartan medoxomil (0, 10, 20, or 40 mg/day) and HCTZ (0, 12.5, or 25 mg/day) (unpublished data, Sankyo Pharma, Inc., 2002). The primary efficacy variable was the mean change in SeDBP from baseline at Week 8.
All olmesartan medoxomil/HCTZ combinations were well tolerated and achieved a significant (P Ͻ .001) reduction in SeSBP and SeDBP compared with placebo (unpublished data, Sankyo Pharma, Inc., 2002). Greater reductions in SeSBP and SeDBP were generally demonstrated with increasing doses of olmesartan medoxomil and with increasing doses of HCTZ (Fig. 6) . The greatest reduction in BP (27.9/21.9 mm Hg) was seen with the olmesartan medoxomil 40-mg/HCTZ 25-mg combination. The incidence of emergent AEs in the olmesartan medoxomil/HCTZ combination groups (44.7% to 56.4%) was comparable to that seen in the placebo group (52.4%). The rate of response, defined as SeDBP Ͻ90 mm Hg or a Ն10-mm Hg reduction from baseline SeDBP, was as high as 92.3% in subjects treated with olmesartan medoxomil/ HCTZ combination therapy and changed in a dose-dependent manner.
Treat-to-Goal Study
In an open-label, multicenter trial, 201 subjects with mildto-moderate essential hypertension (mean SeDBP of 95 to 110 mm Hg) were initially given olmesartan medoxomil 20 mg once daily for 4 weeks. 43 At subsequent 4-week 
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intervals, treatment for subjects who had not reached the BP goal of Յ130/85 mm Hg was modified as follows: uptitration of olmesartan medoxomil to 40 mg/day, addition of HCTZ 12.5 mg/day to the regimen, uptitration of HCTZ to 25 mg/day, addition of amlodipine besylate 5 mg/day, and uptitration of amlodipine besylate to 10 mg/day. Subjects who achieved the BP target at any point would exit the study. The co-primary end points were the percentage of subjects attaining the BP goals of Յ140/90 mm Hg and Յ130/85 mm Hg, respectively. By Week 24, 93.3% of subjects had achieved the BP goal of Յ140/90 mm Hg, and 87.7% of subjects had reached the BP goal of Յ130/85 mm Hg (Fig. 7 ) (see 43 ; unpublished data, Sankyo Pharma, Inc., 2002). In addition, 95% of subjects had reached the SBP goal of Յ140 mm Hg and 97.2% of subjects had reached the DBP goal of Յ90 mm Hg recommended in the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI).
Safety Profile
In an integrated analysis of seven placebo-controlled studies, the incidence of AEs was similar for olmesartan medoxomil and placebo. 20 Most AEs were mild and were not attributed by the investigators to the study drug. The only AE that was reported at least 1% more frequently in olmesartan medoxomil-treated patients than in the placebo group was dizziness (2.8% v 0.9%). Serious AEs were infrequent, occurring in 0.8% of olmesartan medoxomil-treated patients and 0.7% of those given placebo. No statistically significant relationship between olmesartan medoxomil and any severe AE was identified.
Conclusions
Olmesartan medoxomil exhibits dose-related efficacy with a tolerability profile similar to that of placebo at all doses studied (Fig. 8) . Olmesartan medoxomil has also been observed to provide effective BP reduction over a 24-h period with once-daily dosing. In clinical trials comparing it with other antihypertensive agents, olmesartan medoxomil has demonstrated efficacy at least similar to that of the ␤-blocker atenolol and the calcium channel blockers amlodipine besylate and felodipine, and greater antihypertensive efficacy than the ARBs losartan potassium, valsartan, and irbesartan, regardless of the age, sex, or ethnicity of study participants. As a component of the best-tolerated class of antihypertensive agents, olmesartan medoxomil may prove to be a useful addition to our antihypertensive armamentarium.
FIG. 7.
Patients achieving a blood pressure (BP) target by 24 weeks with olmesartan medoxomil-based combination therapy. The percentages of patients reaching the BP goals of Յ140/90 mm Hg and Յ130/85 mm Hg with an olmesartan medoxomil-based treatment regimen were 93.3% and 87.7%, respectively (see 43 ; unpublished data, Sankyo Pharma, Inc., 2002).
FIG. 8.
Blood pressure dose response and adverse events observed during olmesartan medoxomil therapy. Olmesartan medoxomil exhibited dose-related efficacy with a tolerability profile similar to that of placebo (unpublished data, Sankyo Pharma, Inc., 2002). *P Յ .001 v placebo for treatment periods of 6 to 12 weeks; † All adverse events reported, with no causality attributed to the study drug. SeDBP ϭ seated diastolic blood pressure.
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